$ELVN News
Last published 6d ago
- 6d agoELVNEnliven Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 4w agoELVNEnliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearPR NewswireAccomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readinessEnliven continues preparation for late-stage development and commercialization, as it plans to
- 1mo agoELVNEnliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid LeukemiaPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1mo agoELVNEnliven Therapeutics - 1776662 - ENLIVEN THERAPEUTICS INCEarnings Call TranscriptsOkay, good morning everyone. I'm Sean Lyman, Head of US Mid-Cap Biotech Equity Research at Morgan Stanley and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence to make you aware of some importa
- 1mo agoELVNEnliven Therapeutics - Morgan Stanley 24th Annual Global Healthcare Conference - ENLIVEN THERAPEUTICS INCEarnings Call TranscriptsOkay, good morning everyone. I'm Sean Lyman, Head of US Mid-Cap Biotech Equity Research at Morgan Stanley and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence to make you aware of some importa
- 2mo agoELVNEnliven Therapeutics to Present at Upcoming Investor ConferencesPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 2mo agoELVNEnliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 3mo agoELVNEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdatePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 4mo agoELVNEnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 5mo agoELVNEnliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded WarrantsPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 5mo agoELVNEnliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 5mo agoELVNELVN-001: June 2026 Clinical Data Update - ENLIVEN THERAPEUTICS INCEarnings Call Transcripts🎵 We'll be right back. We'll be right back. Thank you. testing audio one two three four five six seven eight it's yes of course it's in the island Thank you. Thank you. We'll be right back. Thank you. Thank you. We'll b
- 5mo agoELVNELVN-001: June 2026 Clinical Data Update - ENLIVEN THERAPEUTICS INCEarnings Call Transcripts🎵 We'll be right back. We'll be right back. Thank you. testing audio one two three four five six seven eight it's yes of course it's in the island Thank you. Thank you. We'll be right back. Thank you. Thank you. We'll b
- 5mo agoELVNEnliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design ComponentsPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 5mo agoELVNJeffries Global Healthcare Conference in New York - ENLIVEN THERAPEUTICS INCEarnings Call TranscriptsHi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Rick Fair, CEO, and Ben Hull, CFO of Enliven. Thanks so much for joining us today. We're going to do fireside
- 5mo agoELVNEnliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 CongressPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 5mo agoELVNEnliven Therapeutics to Present at Upcoming Investor ConferencesPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 6mo agoELVNEnliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CMLPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 6mo agoELVNEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdatePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 8mo agoELVNEnliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdatePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 8mo agoELVNEnliven Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferencePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 10mo agoALLOCHRSELVNONCY+1The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent CliffGlobeNewswireVANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming
- 10mo agoELVNEnliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical MilestonesPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 10mo agoELVNEnliven Therapeutics Bolsters Board to Prepare for Next Phase of DevelopmentPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 11mo agoELVNEnliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing RulesPR NewswireEnliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small...
- 11mo agoELVNEnliven Therapeutics Announces New CEO to Drive Next Phase of DevelopmentPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 12mo agoELVNEnliven Therapeutics Reports Third Quarter Financial Results and Provides a Business UpdatePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual MeetingPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual MeetingPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdatePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 CongressPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics to Present at Upcoming Investor ConferencesPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdatePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 CongressPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual MeetingPR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdatePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoELVNEnliven Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferencePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 1y agoCGEMCRGXDCTHELVN+8Clear Street Launches Healthcare & Biotechnology Equity ResearchBusiness WireComprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a
- 1y agoELVNEnliven Therapeutics Reports Third Quarter Financial Results and Provides a Business UpdatePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 2y agoELVNEnliven Therapeutics to Present at the Jefferies London Healthcare ConferencePR NewswireEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
- 2y agoONCYABBVBGNEHCM+1FDA Approves 16 New Cancer Treatments as Global Cancer Rates SkyrocketPR NewswireUSA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...
- 2y agoELVNEnliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaGlobeNewswireUpdated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to
- 2y agoELVNEnliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CMLGlobeNewswireBOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of
- 2y agoELVNEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateGlobeNewswireDosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the Phase 1a clinical
- 2y agoELVNEnliven Therapeutics to Present at Two Upcoming Investor ConferencesGlobeNewswireBOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small
- 2y agoELVNEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateGlobeNewswireAnnounced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321
- 2y agoELVNEnliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaGlobeNewswireAchieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44%